Retatrutide is an investigational weight loss medication currently undergoing clinical trials and FDA review. At Vitality Aesthetic & Regenerative Medicine in Palm Harbor, FL, we closely monitor emerging metabolic therapies so we can responsibly evaluate new options as they become approved and clinically available.
This page is for educational purposes only. Retatrutide is not currently prescribed at our clinic unless and until it receives appropriate regulatory approval.
Gina Pastore, MSN, ARNP-BC, ABAAHP Anti-Aging Specialist
Retatrutide is a triple hormone receptor agonist currently being studied for chronic weight management.
It targets:
• GLP-1 receptors
• GIP receptors
• Glucagon receptors
By activating all three pathways, retatrutide is designed to influence appetite regulation, energy balance, and fat metabolism simultaneously.
It is still considered investigational and is not yet FDA-approved for weight loss.
Not officially yet. Retatrutide is currently an investigational medication undergoing clinical trials and FDA review. It is not approved for weight loss at this time and is not prescribed at our clinic unless and until regulatory approval is granted. Call us to discuss if this is the treatment you are looking for right now.
Clinical trials suggest that retatrutide may:
• Reduce appetite
• Increase satiety
• Improve insulin sensitivity
• Increase energy expenditure
• Support reduction in body fat
Early studies have demonstrated significant weight reduction in trial participants under controlled conditions.
However, long-term safety and regulatory review are still in progress.
The addition of glucagon receptor activity may influence energy expenditure in addition to appetite control.
Because it affects three pathways, retatrutide is sometimes described as a “triple agonist.”
At this time, retatrutide remains under clinical investigation and is not broadly available as an FDA-approved therapy.
If and when retatrutide becomes approved and clinically appropriate, we will evaluate its role within structured medical weight loss programs.
If approved, retatrutide may be considered for adults who:
• Meet BMI criteria for chronic weight management
• Have metabolic syndrome
• Have not responded to other therapies
• Are medically stable
Eligibility would depend on final FDA indications and safety guidance.
While retatrutide is investigational, we currently offer FDA-approved therapies when appropriate, including:
• Semaglutide
• Tirzepatide
• Structured HCG programs
Treatment selection is based on medical evaluation and clinical eligibility.
As a clinic focused on metabolic health and hormone optimization, we track emerging research so we can responsibly incorporate evidence-based treatments once approved.
Our priority is:
• Safety
• Regulatory compliance
• Long-term metabolic health
• Individualized care
We do not adopt therapies prematurely.
No. Retatrutide is currently in clinical trials and undergoing regulatory review.
Early clinical trials have shown substantial weight reduction in controlled research settings. Final FDA indications and long-term data are still pending.
Not at this time outside of clinical trial settings.
Retatrutide targets three hormonal pathways, while semaglutide and tirzepatide target one or two pathways respectively.
We provide medically supervised weight loss programs in:
If you are exploring advanced metabolic therapies, schedule a consultation to review current FDA-approved options and determine what is appropriate for your health profile.
Speak with our team at 727-771-3915 or fill out the form below to discuss and your health goals.
